Knight Therapeutics Inc.
Knight Therapeutics Inc. (TSX: GUD) is trading at CA$10.35, about ₹700 at today's CAD/INR rate, as of 29 Sep 2026, 4:00 PM ET, up 0.78% today. Indian residents can buy Knight Therapeutics from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
CA$10.16
Today's high
CA$10.41
52 week low
CA$5.66
52 week high
CA$10.41
GUD opened at CA$10.20, closed previously at CA$10.27, and has traded between CA$5.66 and CA$10.41 over the past 52 weeks.
About
Knight Therapeutics Inc., a specialty pharmaceutical enterprise established in Montreal, Canada in 2013, operates globally, with a strong presence across Canada and Latin America. The company's core business revolves around the development, acquisition, in-licensing, out-licensing, promotion, and distribution of a diverse portfolio encompassing pharmaceutical products, consumer health goods, and medical devices. Its extensive product catalog features treatments such as Nerlynx, prescribed for extended adjuvant and metastatic breast cancer; Tafasitamab, used for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib, targeting metastatic cholangiocarcinoma; Trelstar, addressing advanced prostate cancer and pain associated with endometriosis; Vidaza, indicated for myelodysplastic syndrome; Abraxane, for metastatic pancreatic adenocarcinoma; Halaven, for metastatic breast cancer and soft tissue sarcoma; and Lenvima, useful in differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company's offerings further include Ladevina, for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix, for metastatic prostate cancer; Karfib, for relapsed or refractory multiple myeloma; Leprid, for advanced prostate cancer; and Rembre, for chronic myeloid leukemia. For infectious diseases, it provides Ambisome and Cresemba for fungal infections, along with Impavido for leishmaniasis. Other notable products include Exelon, managing mild to moderately severe dementia; Ibsrela, for irritable bowel syndrome with constipation; Salofalk, for ulcerative colitis; Ursofalk, to treat biliary cirrhosis; Imvexxy, for moderate to severe dyspareunia; Bijuva, for moderate to severe vasomotor symptoms linked to menopause in women with intact uteri; Fibridoner, for idiopathic pulmonary fibrosis; Toliscrin DPI, addressing pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2, for severe acute or resistant chronic infections; and Tobradosa Haler, for chronic lung infections. Beyond its product-focused endeavors, Knight Therapeutics Inc. also provides financing to other life science companies and makes strategic investments in life sciences venture capital funds.
Key statistics
Avg. volume
93.36K
Market cap
CA$1.02B
P/E Ratio
70.36
Price-to-sales ratio
1.86
Enterprise value
CA$603.84M
Free cash flow yield
11.35%
Debt-to-equity ratio
0.04
Return on equity
-0.70%
ROIC
-0.20%
Beta
0.05
Dividend yield
0.00%
Last dividend
CA$0.00
Financial overview
Revenue
CA$450.09M
Earnings per share
-CA$0.05
Free cash flow
CA$68.40M
Net profit margin
2.72%
Gross margin
36.88%
EBITDA
CA$54.37M
Revenue growth
21.22%
Similar securities
This is not an investment recommendation
How to buy Knight Therapeutics from India
Indian residents can buy Knight Therapeutics shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to CAD.
Search for Knight Therapeutics and place an order
Find Knight Therapeutics by name or by its ticker, GUD, and choose an order type. Knight Therapeutics trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Knight Therapeutics position in CAD and INR. Knight Therapeutics pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Knight Therapeutics from India
Trading and taxes when buying Knight Therapeutics from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneKnight Therapeutics does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Knight Therapeutics stock?
Yes. Knight Therapeutics (GUD) has been listed on the Toronto Stock Exchange since 2014, in the Drug Manufacturers - Specialty & Generic industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to CAD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Knight Therapeutics share cost in rupees?
One Knight Therapeutics share is CA$10.35 — about ₹700 at a CAD/INR rate of 67.65 on 29 Sep 2026. Both the Knight Therapeutics price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Knight Therapeutics from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
How are gains on Knight Therapeutics shares taxed in India?
Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the CAD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Knight Therapeutics price. Paasa issues a capital-gains statement for your return.
Does Knight Therapeutics pay a dividend?
No. Knight Therapeutics does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Knight Therapeutics from India?
The Toronto Stock Exchange trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when Canada is on standard time. Orders can only execute during that window.
Do I have to declare Knight Therapeutics shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Knight Therapeutics holding, its cost and its closing value.
How do I sell Knight Therapeutics and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in CAD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.
Does the rupee rate affect what I make on Knight Therapeutics?
Yes. Knight Therapeutics is priced in CAD, so your rupee outcome combines the CAD move with the CAD/INR move between the day you remit and the day you convert back. Both directions are reflected in the capital-gains statement Paasa issues.